Ten years real-world experience with sacubitril/valsartan in patients with heart failure with reduced ejection fraction


Por: Savarese, G, Basile, C, Mebazaa, A, Bayes-Genis, A, Kang, SM, Yoo, BS, Eid, C, Bozkurt, B and Butler, J

Publicada: 1 abr 2026
Resumen:
Introduction Sacubitril/valsartan (Sac/Val) represents a cornerstone of heart failure (HF) with reduced ejection fraction (HFrEF) management. This systematic review provides a comprehensive overview of real-world evidence (RWE) regarding the implementation, clinical effectiveness, and safety of Sac/Val in patients with HFrEF.Methods A systematic literature search of PubMed was conducted through March 2024 following PRISMA guidelines.Results The review included 45 manuscripts from 30 different studies, primarily from Europe (44%) and the US (30%). RWE confirmed that Sac/Val was associated with a lower risk of cardiovascular mortality (10%-16%), HF hospitalization (10%-38%), and all-cause mortality (10%-25%). Sac/Val was significantly associated with cardiac reverse remodeling and lower-grade mitral regurgitation. Despite these benefits, implementation gaps persist, with only 15%-25% of patients achieving target doses in clinical practice. The most common reported adverse event with Sac/Val was hypotension (up to 17.6%), though severe hyperkalaemia and renal decline were similar when compared with traditional renin angiotensin system inhibitors.Conclusion Real-world data mirror the efficacy and safety profiles seen in randomized controlled trials, establishing Sac/Val as a cornerstone of HFrEF therapy. However, significant barriers remain, including delayed initiation and suboptimal dose titration. Enhancing clinician and patient awareness is needed to bridge these implementation gaps and fully realize the drug's potential to reduce the global healthcare burden of HF.

Filiaciones:
Savarese, G:
 Karolinska Inst, Sodersjukhuset, Dept Clin Sci & Educ, Sjukhusbacken 10, S-11883 Stockholm, Sweden

Basile, C:
 Karolinska Inst, Sodersjukhuset, Dept Clin Sci & Educ, Sjukhusbacken 10, S-11883 Stockholm, Sweden

 Heart Care Fdn, ANMCO Res Ctr, Florence, Italy

Mebazaa, A:
 Univ Paris Cite, Hop Lariboisiere, AP HP, Paris, France

:
 Hosp Univ Germans Trias I Pujol, Badalona, Barcelona, Spain

Kang, SM:
 Yonsei Univ, Med Coll, Seoul, South Korea

Yoo, BS:
 Yonsei Univ, Wonju Coll Med, Dept Internal Med, Wonju, South Korea

Eid, C:
 Novartis Pharm Serv AG, Dubai, U Arab Emirates

Bozkurt, B:
 Baylor Coll Med, Houston, TX USA

Butler, J:
 Baylor Scott & White Res Inst, Dallas, TX USA

 Univ Mississippi, Coll Med, Jackson, MS USA
ISSN: 20555822





ESC Heart Failure
Editorial
The Heart Failure Association of the European Society of Cardiology, ONE MONTGOMERY ST, SUITE 1200, SAN FRANCISCO, CA 94104 USA, Reino Unido
Tipo de documento: Article
Volumen: 13 Número: 2
Páginas:
WOS Id: 001751552800001
ID de PubMed: 41920861
imagen gold

MÉTRICAS